Bloodstream infections (BSIs) caused by Klebsiella pneumoniae carbapenemases (KPC)-producing K. pneumoniae (KPC-KP) are associated with high mortality rates. We investigated outcomes, risk factors for mortality and impact of appropriate antimicrobial treatment in patients with BSIs caused by molecularly confirmed KPC-KP. All consecutive patients with KPC-KP BSIs between May 2008 and May 2010 were included in the study and followed-up until their discharge or death. Potential risk factors for infection mortality were examined by a case-control study. Case-patients were those who died from the BSI and control-patients those who survived. Appropriate antimicrobial therapy was defined as treatment with in vitro active antimicrobials for at least 48 h. A total of 53 patients were identified.
Introduction
Carbapenems have been widely used as treatment of choice for serious infections caused by ESBL producers, exerting selection pressure for carbapenem resistance [1] . Carbapenem-resistant bacteria have been therefore disseminated and attained high prevalence rates in some regions [2, 3] .
Klebsiella pneumoniae carbapenemases (KPC)-type enzymes are emerging resistance determinants, especially for K. pneumoniae [2, 4] . During the last decade, a rapidly evolving spread of KPC b-lactamases has been documented worldwide, creating an endemic situation in the United States, Israel and more recently in Greece [3] [4] [5] [6] .
Carbapenem resistance among K. pneumoniae isolates represents a major public health issue in Greek hospitals, with resistance rates of up to 37% (EARSS results at http:// www.rivm.nl/earss/result) mainly due to the dissemination of VIM-type carbapenemases [2, 3, 7] . Furthermore, since late 2007, a nationwide spread of KPC enzymes has been documented, creating an emerging concern [5,6].
KPC-associated infections are predominantly nosocomial and systemic infections, affecting patients with multiple risk factors [4, 8] . Therapeutic failures and adverse impact on patient outcome, with high mortality rates ranging from 22% to 57%, have been reported [2] . The antimicrobial treatment options are usually limited to colistin and tigecycline [2, 4] . The optimal treatment for infections caused by KPC-producing bacteria has not yet been established [9] . Many descriptive studies have focused on outbreaks caused by KPC producers, especially in endemic regions. However, data regarding the success rates of different treatment regimens and patient outcomes are still limited.
We present the results of a prospective observational cohort study regarding outcomes, risk factors for mortality and impact of appropriate antimicrobial treatment of bloodstream infections (BSIs) caused by KPC-producing K. pneumoniae (KPC-KP).
Materials and Methods

Study setting, patient population and study design
The study was conducted in Tzaneio General Hospital, Piraeus, Greece, a 480-bed tertiary care hospital having approximately 32 000 admissions each year, and two intensive care units (ICU): a ten-bed general ICU (medical and surgical) and a ten-bed cardiology ICU.
The study population included all consecutive patients with BSIs (documented by at least one positive blood culture and clinical presentation consistent with bacteraemia) caused by KPC-KP between May 2008 and May 2010. Only the first episode per patient was included in our analysis. Patients with polymicrobial bacteraemia were excluded. All patients were followed-up until their discharge or death. The study was observational; administration of antimicrobials and other therapeutic decisions were controlled by patients' physicians in collaboration with infectious disease specialists. A case-control study was conducted between patients who died from BSI (case-patients) and those who survived (control-patients), to detect risk factors associated with infection mortality. We did not include a control group of patients harbouring carbapenemase-negative K. pneumoniae, which are rarely isolated in critically ill patients in our institution; only five BSIs due to such isolates were recorded in our ICU during the study period.
Abstraction of patients' data
Medical records of patients who met the study criteria were reviewed twice a week. Parameters assessed included (i) demographics (age and gender), (ii) ward and duration of hospitalization at isolation, (iii) clinical characteristics, (iv) comor-bidities; (v) invasive procedures (mechanical ventilation, central venous catheter, surgical operations after admission and other interventions), (vi) nosocomial environment exposures (admission from other hospital, prior hospitalization and ICU stay, prior surgery and previous long-term care facility residency), (vii) antimicrobial chemotherapy for current infection, (viii) therapeutic intervention targeting the removal of the probable focus of the infection, such as catheter removal, debridement, drainage or other surgical procedures, and (ix) outcomes (overall in-hospital mortality and infection mortality).
Definitions
BSI onset was defined as the date of collecting the first blood culture yielding study isolate. The probable source (urinary, respiratory, vascular, catheter-related, soft-tissue and primary bacteraemia) was determined on the basis of microbiological results and physicians' findings according to CDC definitions [10] . Catheter-associated BSI was detected by cultures of catheter tips and differential time to positivity. Septic shock was defined as sepsis associated with organ dysfunction and accompanied by persistent hypotension despite volume replacement. Severity of illness on admission and on infection onset was assessed with the APACHE II score [11] . Appropriate empirical antimicrobial treatment referred to administration of in vitro active antimicrobials against the study isolates, within £24 h from infection onset. Appropriate definitive treatment was considered the administration of in vitro active antibiotics for at least 48 h [12] .
Overall mortality included all causes of death during hospitalization. Infection mortality was defined as death mainly attributed to the BSI episode, substantiated by severe sepsis or septic shock and/or multiorgan dysfunction due to the KPC-KP BSI. The possible contribution of the BSI to death was judged by two independent reviewers. The microbiological outcome was classified according to the following definitions: (i) response, study isolate absent in repeat blood cultures obtained during or after the course of antimicrobial therapy; (ii) failure, study isolate present in repeated blood cultures obtained at least 48 h after the treatment initiation; and (iii) indeterminate, repetitive specimens not available for evaluation of microbiological outcome.
Microbiology
Blood cultures were incubated using the BACTEC 9240 Automated Blood Culture System (Becton and Dickinson, Franklin Lakes, NJ, USA). Identification and susceptibility testing of K. pneumoniae blood isolates were performed by the Vitek 2 automated system (bioMerieux, Marcy l' Etoile, France). Colistin and tigecycline MICs were also determined by the CLSI reference broth microdilution method [13] . For tigecycline, the US Food and Drug Administration recommendation was used (susceptible, MIC £ 2 mg/L; resistant, MIC ‡ 8 mg/L) [14] , and for colistin, the EUCAST clinical breakpoints for Enterobacteriacae were applied (susceptible, MIC £ 2 mg/L; resistant, MIC > 2 mg/L; available at http:// www.eucast.org/clinical_breakpoints/).
Screening for phenotypic detection of carbapenemases was performed for all isolates exhibiting reduced susceptibility to carbapenems (MIC > 1 mg/L) by using the modified Hodge test, the combined disk test with imipenem and EDTA [15] , and the combined boronic acid disk tests performed as described previously [16] . The presence of the bla KPC gene and other broad-spectrum b-lactamase genes (ESBLs, plasmidic AmpCs and MBLs) was detected by polymerase chain reaction (PCR) and sequencing [5] .
Surveillance cultures
All patients hospitalized in a general ICU or directly transferred from other institutions to hospital wards were screened for rectal colonization with KPC-KP at admission and once a week during their hospitalization. Rectal swabs were directly plated on MC agar with the addition of 10 lg ertapenem disks [17] and suspected colonies were phenotypically tested for carbapenemase production as described above.
Statistical analysis
Values were expressed as means ± standard deviation (continuous variables) or percentages of the group from which they were derived (categorical variables). The normality of distributions was assessed by the Kolmogorov-Smirnov test. Continuous variables were compared by the Student t-test or the Mann-Whitney U-test, as appropriate. Categorical variables were evaluated by using the chi-square test or Fisher's exact test, as required. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated; two-tailed tests were used to determine statistical significance and p value £0.05 was considered significant. Multivariate analysis was used to identify independent predictors of infection mortality by applying logistic regression. Variables with p value £0.05 in univariate testing were incorporated into the model using a forward stepwise approach. A p value £0.05 was set as the limit for retaining the variables in the model. Statistical analyses were performed by using the SPSS statistical software (version 17; SPSS Inc., Chicago, IL, USA).
Results
A total of 53 patients with BSI caused by KPC-KP were identified during the study period. Most of the patients (38, 71.7%) were hospitalized in the general ICU, while 13 were hospitalized in medical and two in surgical wards, respectively. The probable source of bacteraemia was identified in 30 patients (central venous catheters, 12 patients; respiratory tract, 7; urinary tract, 6; skin or soft tissue, 4; central nervous system, 1 patient), while a source was not detected in the remaining 23 patients. Patients' demographic and clinical characteristics and data for nosocomial environment exposure are presented in Table 1 .
Susceptibility testing showed that 40 (75.5%) KPC-KP were susceptible to colistin, 45 (89.9%) to tigecycline, 51 (96.2%) to gentamicin and 21 (39.6%) to meropenem. It should be noted that most isolates would have been classified as meropenem resistant if the CLSI June 2010 updated breakpoints were available during the study period [18] . All isolates were phenotypically identified as possible KPC-KP by positive modified Hodge test, negative EDTA disk test and positive boronic acid disk test. By PCR all 53 isolates were found to carry bla KPC allele, 46 of them bla SHV and 4 bla CTX-M , shown by sequencing to be bla KPC-2 , bla SHV-12 and bla CTX-M-15 , respectively.
Outcomes of the 53 patients with KPC-KP BSI are shown in Table 2 . Infection mortality was lower among ICU patients (28.9%) vs. non-ICU patients (46.7%, p 0.22), probably due to closer monitoring of ICU patients. The mean time from BSI onset to death was 7.3 days.
Appropriate antimicrobial treatment, which lasted at least 48 h, was administered to 35 patients. Infection mortality in the appropriately treated patients was 20%, being significantly lower than infection mortality of patients who did not receive appropriate treatment (61.1%, p 0.003). Appropriate empirical treatment was administered to 14 patients (seven with severe sepsis) and infection mortality among them was similar to that of patients who did not receive appropriate empirical treatment (35.7% vs. 33.3%, p 0.87). Timely initiation of active antimicrobials (within 3 days) was noted for 17 of the 35 patients who received appropriate antimicrobial treatment, with no significant impact on patient survival (infection mortality 23.5% vs. 16 .7%, p 0.69). Combination schemes were received by 20 appropriately treated patients and all of them survived. In contrast, infection mortality among 15 patients administered monotherapy, mainly colistin or tigecycline, was significantly higher (46.7%, p 0.001). The most common treatment regimen was the combination of colistin with tigecycline, received by nine patients. Colistin was used as monotherapy in seven patients with infection mortality 66.7%, while tigecycline monotherapy was administered to five patients with infection mortality 40% (Table 3 ).
In the univariate analysis, several factors were significantly associated with infection mortality (Table 1) . Patients who survived were significantly younger (p <0.001) and more often had prior ICU-hospitalization (p 0.06), prior surgical operations (p 0.014) and central venous catheters at isolation time (p 0.014). Catheter-related bacteraemia was significantly associated with survival (p 0.04). APACHE II scores at admission and at infection onset were significantly higher among non-survivors (p <0.001). Presentation with severe sepsis or septic shock was also significantly associated with infection mortality (p <0.001). Appropriate antimicrobial treatment (p 0.003), combination schemes (p 0.001) and other therapeutic interventions targeting the removal of the focus of infection (p 0.015) were strongly correlated with survival.
The results of the final multivariate model are shown in Table 4 . Patient's age, APACHE II score at infection onset and inappropriate antimicrobial therapy were independent predictors of infection mortality. To further evaluate the impact on survival of the appropriate antimicrobial treatment, a second multivariate model was built by retaining appropriate antimicrobial treatment adjusted by the more significant potential confounders, age, APACHE II at infection onset, severe sepsis or septic shock and other therapeutic interventions. No significant differences were observed between these two models (data not shown), underlining the importance of appropriate antimicrobial treatment.
Discussion
The global spread of KPC-KP poses remarkable clinical and therapeutic challenges. The increasing prevalence of severe KPC infections, with high mortality rates, underlines the need for effective treatment [2, 9] . However, the optimal treatment for infections caused by KPC-producing bacteria has not yet been determined. Although several studies have described outbreaks caused by KPC producers, there is a scarcity of data to provide therapeutic recommendations based on clinical evidence from well-defined prospective studies [9] . Our study involved a series of 53 patients with KPC-BSI. The clinical profile of the patients was similar to that reported in other studies of KPC-KP infections [2, 8] . Half of our patients were colonized by KPC-KP prior to the BSI; a similar colonization rate was observed in another study [6] . The previously reported high rate of subsequent clinical infection among silent carriers highlights the value of active surveillance [19] . Information about colonization status apart from infection control benefits is crucial for the choice of empirical treatment in septic patients.
The overall mortality in our patients was high (52.8%), similar to that observed in other studies [6, [20] [21] [22] , probably reflecting critical status as measured by the APACHE II score at admission. The infection mortality in our cohort (34%), exclusively including patients with BSI, was also relatively high. However, the 14-day mortality rate (28.3%) was lower than that reported previously among 19 patients with KPC-KP bacteraemia (47%) [20] .
To further investigate the KPC-KP infection mortality, we evaluated the influence of patient, isolate and infection characteristics, along with therapeutic interventions, on infection mortality. These parameters were assessed in patients who died from compared with those who survived KPC-KP BSI; this approach was mainly intended to identify specific factors associated with the infection mortality and possibly highlight implications for the management of these infections. Appropriate antimicrobial treatment had a significant impact on patient outcome. In contrast, appropriate empirical treatment and initiation of active antimicrobials within 3 days was not associated with favourable infection outcome; this finding could possibly be explained by the more frequent presentation with severe sepsis in this subgroup. In the single previous report on the impact of antimicrobial and adjunctive therapies on outcomes, receipt of antibiotics with in vitro activity against KPC-KP was not associated with patient survival [23] . Our study also demonstrated a superiority of combination treatment. Tigecycline with colistin was the most common combination scheme; its effectiveness is supported by recently published time-kill results [24] . It is of note that infection mortality among patients who received colistin monotherapy is similar to that in those who received inappropriate antimicrobial treatment. Apart from the nonfavourable outcome of colistin-treated patients, colistin resistance has also emerged in our settings [25] , suggesting that colistin monotherapy should be given with caution. Regarding carbapenems, frequent clinical and microbiological failures were observed previously when KPC infections caused by carbapenem-susceptible isolates were treated with carbapenem monotherapy [26] .
A non-identifiable source of bacteraemia was correlated with poor outcome, almost reaching statistical significance, while catheter-related bacteraemia was significantly associated with survival. These findings suggest the importance of interventions targeting the focus of infection, which were significantly correlated with survival. Adjunctive therapies were also independently associated with survival in other reports [23] .
Older age and higher APACHE II score at admission and at infection onset, along with presentation with severe sepsis or septic shock, were the main predictors of infection mortality. Unexpectedly, prior hospitalization in an ICU was associated with favourable infection outcome. It could be suggested that a prior ICU stay led to more effective empirical treatment due to high clinical suspicion for carbapenemase producers, which are common in Greek ICUs [2] .
Overall, it is evident that KPC-KP BSIs are associated with high mortality rates. According to the results of the multivariate analysis, the major predictors of infection mortality were severity of the baseline condition, older age and inappropriate treatment. Among them, the only modifiable variable that could be used to improve outcomes is the administration of appropriate treatment. It is thus critical, further to infection control strategies, to identify patients at risk of adverse outcome and ensure effective treatment based on sufficient evidence.
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